CIK 0001492674
TTOO T2 Biosystems, Inc.
Insider trading from SEC Form 4. Last filing Jan 2, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at T2 Biosystems, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 8 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 4, 2024 | Laura Lee Adams director | AGrant or award Restricted Stock Unitsderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 2, 2025 |
| Nov 4, 2024 | John W Cumming director | AGrant or award Restricted Stock Unitsderivative | +35,000 | $0.00 | $0 | 35,000 | Jan 2, 2025 |
| Nov 4, 2024 | David B Elsbree director | AGrant or award Restricted Stock Unitsderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 2, 2025 |
| Nov 4, 2024 | Michael Terrence Gibbs General Counsel | AGrant or award Restricted Stock Unitsderivative | +190,000 | $0.00 | $0 | 190,000 | Jan 2, 2025 |
| Nov 4, 2024 | Brett A. Giffin Chief Commercial Officer | AGrant or award Restricted Stock Unitsderivative | +180,000 | $0.00 | $0 | 180,000 | Jan 2, 2025 |
| Nov 4, 2024 | Seymour Liebman director | AGrant or award Restricted Stock Unitsderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 2, 2025 |
| Nov 4, 2024 | Michael Terrence Gibbs General Counsel | AGrant or award Restricted Stock Unitsderivative | +190,000 | $0.00 | $0 | 190,000 | Jan 2, 2025 |
| Nov 4, 2024 | Brett A. Giffin Chief Commercial Officer | AGrant or award Restricted Stock Unitsderivative | +180,000 | $0.00 | $0 | 180,000 | Jan 2, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Laura Lee Adamsdirector
- John W Cummingdirector
- David B Elsbreedirector
- Michael Terrence GibbsGeneral Counsel
- Brett A. GiffinChief Commercial Officer
- Seymour Liebmandirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.